YLYang Li

Yang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Li has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Feng Yang

    Sichuan Key Laboratory of Medical Imaging, Department of Radiology, The Affiliated Hospital of North Sichuan Medical College, Nanchong City, China

    4 shared publications
  • Jin Hong Yu

    Sichuan Key Laboratory of Medical Imaging, Department of Ultrasound, The Affiliated Hospital of North Sichuan Medical College, Nanchong City, China

    4 shared publications
  • Chaofeng Yang

    Sichuan Key Laboratory of Medical Imaging, Department of Radiology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, China

    2 shared publications
  • Hui Zuo

    Sichuan Key Laboratory of Medical Imaging, Department of Ultrasound, The Affiliated Hospital of North Sichuan Medical College, Nanchong City, China

    2 shared publications
  • Jinhong Yu

    Affiliated Hospital of North Sichuan Medical College

    2 shared publications
  • Juying Zhang

    Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Innovation Centre for Science and Technology of North Sichuan Medical College, Nanchong, Sichuan, 637000, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Therapeutic Potential of PDA@CeO2 in Suppressing Hepatic Stellate Cell Activation and Preventing Liver Fibrosis

    by Han-Mei Li, Ju-Ying Zhang, Xiao-Qing Wang, Li-Tao Ye, Bo Ren, Yi-Han Leng, Ji-Xuan Zhang, You Yang, Qiong Jiang, Lin-Li Feng, et al.

    Objective: Liver fibrosis replaces healthy tissue with scar tissue, potentially leading to cirrhosis and cancer. ROS drive this process by activating hepatic stellate cells. This study tests the hepatoprotective effects of PDA@CeO2 nanoparticles in scavenging ROS, inhibiting HSC activation, and delaying fibrosis, using 2D-SWE to assess treatment efficacy. Methods: In vitro, flow cytometry evaluated ROS levels in HSCs, scratch assays assessed migration, and α-SMA expression confirmed activation. In vivo, PDA@CeO2 NPs were tested in rats with CCl4-induced liver fibrosis, with effects monitored by 2D-SWE. Histopathological staining and fibrosis markers (Collagen I, α-SMA, TGF-β/Smad3, NOX4) assessed fibrosis progression. Results: In vitro, PDA@CeO2 reduced ROS levels and inhibited HSC migration, with decreased α-SMA expression indicating suppressed activation. In vivo, PDA@CeO2 treatment in CCl4-induced liver fibrosis rats reduced fibrosis markers. 2D-SWE showed improved liver stiffness, and histopathological analysis revealed reduced fibrosis and inflammation. The therapeutic effects were linked to modulation of the NOX4-TGF-β/Smad3 pathway, attenuating fibrosis progression. Conclusion: This study demonstrates the potential of PDA@CeO2 NPs as a novel treatment for liver fibrosis. These nanoparticles scavenge ROS and modulate inflammatory pathways, targeting key signaling mechanisms like the NOX4-TGF-β/Smad3 pathway. PDA@CeO2 NPs offer a promising strategy for attenuating fibrosis at cellular and molecular levels. Additionally, 2D-SWE provides a non-invasive tool for monitoring therapeutic outcomes, positioning PDA@CeO2 NPs as a promising candidate for future clinical liver fibrosis treatments.


  • Open Access

    Asialoglycoprotein receptor-targeted perfluorooctylbromide as a targeted contrast agent for evaluating the severity of carbon tetrachloride-induced acute liver damage in rats

    by Jinhong Yu, Chaofeng Yang, Pengwei Zhang, Min Wei, Yang Li

    Asialoglycoprotein receptor (ASGPR) is an endocytic C-type lectin receptor in hepatocytes. Acute and chronic liver diseases can result in the decreased expression and content of this receptor. The objective of this study was to determine whether ASGPR-targeted perfluorooctylbromide (PFOB) can enhance ultrasound imaging signals and evaluate the severity of carbon tetrachloride (CCl4)-induced acute liver damage in rats. The specificity of ASGPR-targeted PFOB for hepatocytes L-02 was investigated in vitro. In vivo, all rats were treated with either ASGPR-targeted PFOB or PFOB, and ultrasound imaging of the livers was performed to evaluate the effect of these treatments on the imaging signal. The effects of CCl4 injection were also examined by measuring the percentage of apoptotic hepatocytes and ASGPR content. We first confirmed that ASGPR-targeted PFOB can be targeted specifically to hepatocytes L-02. In the healthy rat group, ASGPR-targeted PFOB increased the echo intensity (EI) of the liver by 87.47 dB, which was significantly higher than the EI increase observed with PFOB treatment (37.38 dB; P < 0.001), and the mean elimination times of the contrast agents were 282 ± 13.17 min and 225 ± 10.80 min for the ASGPR-targeted PFOB and PFOB groups, respectively (P < 0.001). In the CCl4-induced acute liver injury group, significant differences were observed in each group before and after administration of ASGPR-targeted PFOB. Significant differences were also observed between the different groups. The degree of reduction in peak EI correlated with the total dose of the CCl4. A decline in ASGPR content was correlated with the severity of acute liver damage using the CCl4-induced model. These findings suggest that ASGPR-targeted PFOB enhances ultrasound imaging and is a reliable tool for assessing the severity of acute liver damage in rats.


  • Open Access

    Ferroptosis boosting system based on a sonodynamic therapy cascade-augmented strategy for triple-negative breast cancer therapy

    by Juying Zhang, Hanmei Li, Litao Ye, Yihan Leng, Xiaoqing Wang, You Yang, Qiong Jiang, Linli Feng, Ling Li, Yang Li, et al.

    One of the novel forms of programmed cell death, ferroptosis, has recently emerged as a hopeful treatment strategy for triple-negative breast cancer (TNBC). However, insufficient levels of intracellular reactive oxygen species (ROS) and high levels of ROS scavengers in the tumor microenvironment (TME), such as glutathione (GSH), hamper the efficacy of ferroptosis therapy. In this study, the introduction of manganese dioxide nanoparticles (MnO2 NPs) generated cytotoxic hydroxyl radicals (⋅OH) in the TME. Importantly, MnO2 NPs act as a nanosensitizer by consuming H2O2/GSH in the TME, generating oxygen (O2) to relieve the oxygen deficiency of tumors, induce tumor oxidative stress and ultimately enhance SDT-induced ferroptosis. Additionally, oxygen, as an ultrasound contrast agent, enables the visualization of the TNBC treatment process. Meanwhile, GSH depletion in the TME leads to failure of the major cellular system defending against ferroptosis, which also promotes the accumulation of lipid peroxidation in tumor tissue. Specifically, robust autophagy induced by ROS enhances the intracellular iron pool by breaking down ferritin, thereby promoting ferroptosis in cancer cells, leading to the optimal antitumor effect. Consequently, a ferroptosis boosting system that simultaneously encapsulates MnO2 NPs and chlorin e6 (Ce6) was constructed for the intervention of TNBC. Both the in vitro and in vivo results demonstrated that Ce6-MnO2-BSA nanoparticles can generate a significant ROS storm under ultrasound irradiation, eliminating GSH and inducing an autophagic response that increases the effectiveness of ferroptosis, thus, inhibiting the growth of TNBC without obvious toxic side effects. This effective strategy can cascade-augment cancer cell ferroptosis, providing a new perspective for the clinical treatment of TNBC.


  • Open Access

    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis

    by Min Wei, Pengwei Zhang, Chaofeng Yang, Yang Li

    Objectives: This study aimed to evaluate the effectiveness of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and programmed cell death protein 1 (PD-1) inhibitors in the treatment of advanced, unresectable hepatocellular carcinoma (HCC).Methods: A comprehensive search across multiple databases was conducted to identify relevant studies published up to May 2024. This search focused on clinical trials investigating the combination of HAIC with lenvatinib and PD-1 inhibitors for the treatment of advanced HCC. Data from these trials were analyzed using either fixed-effects or random-effects models, with results reported as hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs). To evaluate the robustness of the findings, trial sequential analysis was employed.Results: A total of 8 cohort studies encompassing 1073 patients with unresectable HCC were included. Compared with other treatment regimens, the combined use of HAIC, lenvatinib, and PD-1 inhibitors significantly improved overall survival (OS) (HR=0.53 [95% CI 0.45, 0.63], P<0.00001), progression-free survival (PFS) (HR 0.56 [95% CI 0.46, 0.61], P<0.0001), the objective response rate (ORR) (RR=1.82 [95% CI 1.52, 2.18], P<0.00001), and the disease control rate (DCR) (RR=1.24 [95% CI 1.16, 1.33], P<0.00001). Trial sequential analysis (TSA) results indicated that the existing data were sufficient for making quantitative conclusions about the ORR and DCR.Conclusion: Combining HAIC with lenvatinib and PD-1 inhibitors enhances the effectiveness of treatment for unresectable HCC. This approach is particularly beneficial for patients who have a high tumor burden or those who are refractory to transarterial chemoembolization (TACE), providing a more effective solution for these challenging cases.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024575853, identifier CRD42024575853.


  • Open Access

    5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis

    by Min Wei, Pengwei Zhang, Chaofeng Yang, Menglin Luo, Chengxi Zeng, Yujie Zhang, Yang Li

    This study aimed to assess the effectiveness and safety of 5-Fluorouracil (5-Fu) combined with conventional transarterial chemoembolization (cTACE) compared to 5-Fu combined with drug-eluting bead transarterial chemoembolization (DEB-TACE) using CalliSpheres for the treatment of unresectable hepatocellular carcinoma (HCC) using propensity score weighting methods. This retrospective analysis included 131 patients with HCC treated with 5-Fu combined with cTACE (5-Fu-cTACE group, n = 65) or DEB-TACE (5-Fu-DEB-TACE group, n = 66) at the Affiliated Hospital of North Sichuan Medical College from January 2019 to December 2022. Based on the baseline data and laboratory indicators, propensity score weighting was used to reduce confounding bias. Modified response evaluation criteria in solid tumors (mRECIST) were used to evaluate clinical efficacy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were the disease control rate (DCR), objective response rate (ORR) and adverse events (AEs). PFS was assessed using Kaplan‒Meier analysis and Cox proportional hazards models. The ORRs at 1 month (M1) after treatment in the 5-Fu-DEB-TACE group and 5-Fu-cTACE group were 90.9% and 76.9%, respectively (P = 0.029), while at this time, the DCRs were 93.9% in the 5-Fu-DEB-TACE group and 90.8% in the 5-Fu-cTACE group (P = 0.494). At 3 months (M3) after treatment, the 5-Fu-DEB-TACE group had a higher ORR (84.8% vs. 56.9%, P < 0.001) and DCR (84.8% vs. 72.3%, P = 0.08). The ORR at 6 months (M6) was also higher in the 5-Fu-DEB-TACE group than in the 5-Fu-cTACE group (72.7% vs. 50.8%, P = 0.01). The median PFS after treatment with 5-Fu-DEB-TACE was longer than that after treatment with 5-Fu-cTACE (11 months vs. 6 months) (P = 0.004). Cox proportional hazards regression analysis indicated that 5-Fu-DEB-TACE (HR = 0.590, P = 0.044), Model for End-Stage Liver Disease (MELD) intermediate risk (HR = 2.470, P = 0.010), BCLC stage B (HR = 2.303, P = 0.036), BCLC stage C (HR = 3.354, P = 0.002) and ascitic fluid (HR = 2.004, P = 0.046) were independent predictors of PFS. No treatment-related deaths occurred in this study. The 5-Fu-DEB-TACE group had a greater incidence of abdominal pain (72.7% vs. 47.7%, P = 0.003). However, the incidence of postoperative elevated transaminase levels was higher in the 5-Fu-cTACE group (83.1% vs. 66.6%, P = 0.031). Subgroups analysis showed patients receiving 5-Fu-DEB-TACE have better PFS compared to those receiving 5-Fu-cTACE in the BCLC stage A group (P = 0.0093), BCLC stage B group (P = 0.0096), multifocal group (P = 0.0056), Child-Pugh stage A group (P<0.001), non- extrahepatic metastasis group (P = 0.022), non-vascular invasion group (P = 0.0093), and the group with a largest tumor diameter ≥ 5 cm (P = 0.0048). At M1, M3, and M6, patients with preserved liver function and in some cases of low tumor burden had higher Objective Response Rate (ORR) and Disease Control Rate (DCR) (P < 0.05). Compared with 5-Fu-cTACE, 5-Fu-DEB-TACE has superior therapeutic efficacy, prolongs PFS, and reduces hepatotoxicity. However, it is associated with an increased incidence of postoperative abdominal pain.


  • Open Access

    Giant renal schwannoma with obvious hemorrhage and cystic degeneration: a case report and literature review

    by Chao Feng Yang, Hui Zuo, Jin Hong Yu, Sushant Kumar Das, Yang Li

    Background: Renal schwannomas are very rare and are usually benign. Its clinical symptoms and imaging features are nonspecific, and the diagnosis is usually confirmed by pathology after surgical resection. Case presentation: A 46-year-old Chinese female was admitted to the hospital with right flank pain that had persisted for the six months prior to admission. This pain had worsened for 10 days before admission, and dyspnea occurred when she was supine and agitated. A right abdominal mass could be palpated on physical examination. Computed tomography and magnetic resonance imaging examinations revealed a large, nonenhanced, cystic and solid mass in the right kidney. The patient received radical nephrectomy for the right kidney. The diagnosis of schwannoma was confirmed by pathological examination. Conclusions: We report a case of a large renal schwannoma with obvious hemorrhage and cystic degeneration, which can be used as a reference for further study.


  • Open Access

    Small (≤ 20 mm) ground-glass opacity pulmonary lesions: which factors influence the diagnostic accuracy of CT-guided percutaneous core needle biopsy?

    by Yang Li, Chao Feng Yang, Jun Peng, Bing Li, Chuan Zhang, Jin Hong Yu

    Background: The diagnostic accuracy of computed tomography (CT)-guided percutaneous core needle biopsy (CNB) for small (≤ 20 mm) ground-glass opacity (GGO) lesions has not been reported in detail. Objectives: To evaluate factors that affect the diagnostic accuracy of CT-guided percutaneous CNB for small (≤ 20 mm) GGO pulmonary lesions. Methods: From January 2014 to February 2018, 156 patients with a small (≤ 20 mm) GGO pulmonary lesion who underwent CT-guided CNB were enrolled in this study. Factors affecting diagnostic accuracy were evaluated by analyzing patient and lesion characteristics and technical factors. Significant factors were identified by multivariate logistic regression. Results: The diagnostic accuracy of CT-guided percutaneous CNB was 90.4% for small (≤ 20 mm) GGO pulmonary lesions. The diagnostic accuracy was higher for larger lesions (72.5% for lesions ≤ 10 mm, 96.6% for lesions between 11 and 20 mm [P < 0.001]). The diagnostic accuracy of CT-guided percutaneous CNB was 74.5% for lesions with > 90% GGO components and 97.2% for lesions with 50–90% GGO components (P < 0.001). In multivariate analysis, the significant factors influencing diagnostic accuracy were lesion size (P = 0.022; odds ratio [OR] for a lesion between 11 and 20 mm in size was approximately 5 times higher than that for a lesion ≤ 10 mm; 95% confidence interval [CI], 1.3 to 18.5), and GGO component (P = 0.015; OR for a lesion with 50–90% GGO components was approximately 6 times higher than that for a lesion with > 90% GGO components; 95% CI: 1.4 to 25.7). Conclusions: Lesion size and GGO component are factors affecting diagnostic accuracy. The diagnostic accuracy was higher for larger lesions and lesions with 50–90% GGO components.


  • Open Access

    The Usefulness of MRI R2* Value In Diagnosing And Staging of Rat Liver Fibrosis

    by Jin Hong Yu, Chao Feng Yang, Hui Zuo, Sushant Kumar Das, Yang Li

    Background: Liver fibrosis involves the increase of iron deposition. however, whether R2* measurement can be used as a noninvasive method to characterize processes of fibrogenesis with iron deposition is not clear. This study aims at assessing the usefulness of magnetic resonance imaging (MRI) R2* value in diagnosing and staging of rat liver fibrosis. Methods: Male Sprague-Dawley rats were injected intraperitoneally with a mixture of 1.0 ml/kg carbon tetrachloride (CCl4) and oil (1:1 v/v) twice a week for 12 weeks. Liver R2* value was quantitatively determined by multi - echo fast gradient echo sequence. Liver iron content (LIC) was evaluated by an atomic absorption spectrophotometer. The stage of liver fibrosis was assessed by pathological METAVIR scores. The performances of R2* values for each fibrosis stage were evaluated. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff values for fibrosis stage. Results: R2* values and LIC gradually increased during the progression of the liver fibrosis, the correlation between the R2* values and the LIC was high-positive. There were significant differences in R2* values among the stages of liver fibrosis (F= 30.84,P < 0.001). There was a significant positive correlation between R2* values and LIC (r= 0.984, P < 0.001). The most discriminating cutoff values of R2* were 46.84 Hz for ≥ F1, 55.30 Hz for ≥ F2, 68.06 Hz for ≥ F3, and 78.79 Hz for F4. Conclusion: R2* values can be used for detecting and staging liver fibrosis. The degree of liver fibrosis was related to the degree of increase in R2* measurements.

  • Open Access

    Asialoglycoprotein Receptor-Targeted Superparamagnetic Perfluorooctylbromide Nanoparticles

    by Yang Li, Chao Feng Yang, Hui Zuo, Ao Li, Sushant Kumar Das, Jin Hong Yu

    Background. The decrease in asialoglycoprotein receptor (ASGPR) levels is observed in patients with chronic liver disease and liver tumor. The aim of our study was to develop ASGPR-targeted superparamagnetic perfluorooctylbromide nanoparticles (M-PFONP) and wonder whether this composite agent could target buffalo rat liver (BRL) cells in vitro and could improve R2 value of the rat liver parenchyma after its injection in vivo. Methods. GalPLL, a ligand of ASGPR, was synthesized by reductive amination. ASGPR-targeted M-PFOBNP was prepared by a film hydration method coupled with sonication. Several analytical methods were used to investigate the characterization and safety of the contrast agent in vitro. The in vivo MR T2 mapping was performed to evaluate the enhancement effect in rat liver. Results. The optimum concentration of Fe3O4 nanoparticles inclusion in GalPLL/M-PFOBNP was about 52.79 µg/mL, and the mean size was 285.6 ± 4.6 nm. The specificity of GalPLL/M-PFOBNP for ASGPR was confirmed by incubation experiment with fluorescence microscopy. The methyl thiazolyl tetrazolium (MTT) test showed that there was no significant difference in the optical density (OD) of cells incubated with all GalPLL/M-PFOBNP concentrations. Compared with M-PFOBNP, the increase in R2 value of the rat liver parenchyma after GalPLL/M-PFOBNP injection was higher. Conclusions. GalPLL/M-PFOBNP may potentially serve as a liver-targeted contrast agent for MR receptor imaging.